HC Q study #87
See all studies
Late treatment study
Catteau et al., Int. J. Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106144 (Peer Reviewed)
Low-dose Hydroxych loroquine Therapy and Mortality in Hospitalized Patients with COVID-19: A Nationwide Observational Study of 8075 Participants
Retrospective 8,075 hospitalized patients, 4,542 low-dose HC Q, 3,533 control. 35% lower mortality for HC Q (17.7% vs. 27.1%), adjusted HR 0.68 [0.62–0.76]. Low-dose HC Q monotherapy was independently associated with lower mortality in hospitalized patients.
Patients exposed to others therapies (TCZ, AZ, LPV/RTV) were excluded.
Statistical analysis was performed by an independent group. Calendar time of prescription and immortal time bias was taken into account. Corticosteroids prescriptions was low in both groups.
Source   Share   Tweet
See all studies
Please send us corrections, updates, or comments.